Abstract:CXCR4/CXCL12 axis plays an important role in tumor growth, angiogenesis, metastasis, and therapeutic resistance. The aim of this study is to perform a meta-analysis and literature review to evaluate the association of CXCR4 expression with clinicopathological significance and prognosis in patients with prostate cancer (PCa). A detailed literature search was made in Medline, EMBASE, Web of Science, and Google Scholar for related research publications. The data were extracted and assessed independently. Analysis of pooled data was performed using Review Manager 5.2. Odds ratio (OR) with corresponding confidence intervals were calculated and summarized. The meta-analysis included a total of eleven studies and 630 patients. The rate of CXCR4 protein expression in PCa was significantly higher than in nonmalignant prostate tissues (OR = 35.71, P<0.00001). The expression of CXCR4 protein was not significantly associated with Gleason score (P=0.73). However, the frequency of CXCR4 protein expression was significantly higher in T3-4 stage than in T1-2 stage of PCa (OR = 2.35, P=0.001). The expression of CXCR4 protein was significantly associated with the presence of lymph node and bone metastasis of PCa: for lymph node metastasis positive versus negative, OR was 5.07 and P=0.0003, and for bone metastasis positive versus negative, OR was 7.03 and P=0.003. Cancer-specific survival of patients with PCa was significantly associated with CXCR4 protein expression, and the pooled Hazard ratio was 0.24 and P= 0.002. In conclusion, the high expression of CXCR4 protein is a diagnostic biomarker of PCa, and it is significantly associated with T stages. The increased expression of CXCR4 protein is significantly associated with lymph nodes or bone metastasis, and CXCR4 is a poor prognosis predictor for patients with PCa. Taken together, our findings indicate that CXCR4 could be a target not only for the development of therapeutic intervention but also for the noninvasive monitoring of PCa progression.

The Role of CXCR7/RDC1 As a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer.

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Data from Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer

Ccr2 Expression Correlates With Prostate Cancer Progression

Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer

CCR7 regulates cell migration and invasion through MAPKs in metastatic squamous cell carcinoma of head and neck

Cxcr6 Induces Prostate Cancer Progression By The Akt/Mammalian Target Of Rapamycin Signaling Pathway

Effect of CXCR7 on Tumor Development,Angiogenesis and Immune Reaction

Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition

The Role of CXCR3 and Its Ligands in Cancer

CXCR7 in tumorigenesis and progression.

CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering

Expression of Chemokine Receptor CXCR7 in Colorectal Carcinoma and Its Prognostic Significance.

CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies

Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression

Data from CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes

The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review

CCL2/CCR2 signaling in cancer pathogenesis

Chemokine-chemokine Receptor Pathway As a Tumor Therapeutic Target: the Significance of SDF-1CXCR4 Pair